# Merck & Co., Inc. – Consensus ‘buy’ rating and 27.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/merck-co-inc-consensus-buy-rating-and-27-8-upside-potential/4121184546
- Published: 2025-01-22T13:46:25+00:00
- Author: Charlotte Edwards

**Merck & Co., Inc.** which can be found using ticker (MRK) have now 24 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $150.00 and $100.00 calculating the average
target price we see $125.13. Now with the previous closing price of $97.92 this 
indicates there is a potential upside of 27.8%. The 50 day MA is $99.97 and the 
200 day moving average is $115.60. The company has a market cap of 243.45B. Currently
the stock stands at: $96.24 USD

 The potential market cap would be $311,108,283,128 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 20.13, revenue per share of $24.93
and a 10.53% return on assets.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions
through its prescription medicines, including biological therapies, vaccines and
animal health products. It operates through two segments: Pharmaceutical and Animal
Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine
products. Its human health pharmaceutical products consist of therapeutic and preventive
agents, generally sold by prescription for the treatment of human disorders. The
Company sells these human health pharmaceutical products primarily to drug wholesalers
and retailers, hospitals, government agencies and managed healthcare providers, 
such as health maintenance organizations. The Animal Health segment develops, manufactures
and markets a range of veterinary pharmaceutical and vaccine products, as well as
health management solutions and services for the prevention, treatment and control
of disease in all major livestock and companion animal species.

Share on:
